Summary The Translational Genomics Research Institute (TGen), formerly Arizona Bioscience and Bio-medicine Institute is a non-profit organization that develops earlier diagnostics and treatments. The organization conducts clinical trials to investigate new chemical agents for the treatment pancreatic cancer, breast cancer, leukemia, prostate cancer, and others. It offers clinical trials such as lung cancer and melanoma and incorporate novel tools for identifying patients' genomic characteristics for more targeted approach. TGen employs advances from the human genome project to develop prognostics, diagnostics, and therapies for treatment of neurological disorders, cancer, diabetes and other complex diseases. The organization also conducts research programs for finding new therapies for the treatment of autism, breast cancer, diabetes, gastric cancer, melanoma and prostate cancer, among others. It operates through its research units. TGen is headquartered in Phoenix, Arizona, the US. The Translational Genomics Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and... Research Beam Model: Research Beam Product ID: 2637743 250 USD New
The Translational Genomics Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

The Translational Genomics Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : October   2017
  • Pages : 39
  • Publisher : GlobalData
 
 
 
Summary

The Translational Genomics Research Institute (TGen), formerly Arizona Bioscience and Bio-medicine Institute is a non-profit organization that develops earlier diagnostics and treatments. The organization conducts clinical trials to investigate new chemical agents for the treatment pancreatic cancer, breast cancer, leukemia, prostate cancer, and others. It offers clinical trials such as lung cancer and melanoma and incorporate novel tools for identifying patients' genomic characteristics for more targeted approach. TGen employs advances from the human genome project to develop prognostics, diagnostics, and therapies for treatment of neurological disorders, cancer, diabetes and other complex diseases. The organization also conducts research programs for finding new therapies for the treatment of autism, breast cancer, diabetes, gastric cancer, melanoma and prostate cancer, among others. It operates through its research units. TGen is headquartered in Phoenix, Arizona, the US.

The Translational Genomics Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
The Translational Genomics Research Institute, Medical Devices Deals, 2011 to YTD 2017 9
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
TGen Enters into Research Agreement with Baylor Research Institute 11
BIO5 Oro Valley Enters Into Co-Development Agreement With TGen For Alzheimer’s Disease 12
Virginia G. Piper Cancer Center And TGen Enter Into Co-Development Agreement With Samuel Oschin Comprehensive Cancer Institute 13
Licensing Agreements 14
Oncoholdings Receives License For ONCO-101 From The Translational Genomics Research Institute 14
The Translational Genomics Research Institute - Key Competitors 15
The Translational Genomics Research Institute - Key Employees 16
The Translational Genomics Research Institute - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 18
Recent Developments 19
Corporate Communications 19
Aug 25, 2016: Nov. 6 StepNout 5K Aims for Another $1 illion for TGen Cancer Research 19
Jul 27, 2016: Cycle for the Cure raises a record $248,725 for cancer research at TGen 21
Government and Public Interest 23
Jul 24, 2017: ASU-TGen study identifies new brain death pathway in Alzheimer’s disease 23
Jan 23, 2017: Hearst Foundation funds TGen research into cancer-related 'wasting syndrome' 25
Aug 12, 2016: SmartPractice Donates $50,000 to TGen Cancer Research 26
May 09, 2016: TGen and International Team Find New Avenues of Precision Medicine for Treating Cancer 27
May 02, 2016: TGen SU2C Melanoma Dream Team Member Receives $200,000 Sharp Award 29
Apr 01, 2016: TGen and Mayo Clinic scientists issue report in Cell on advances in basal cell carcinoma treatment 31
Mar 21, 2016: Beyond DNA: TGen points the way to Enhanced Precision Medicine with RNA Sequencing 32
Mar 17, 2016: TGen helps track down deadly infection 34
Product News 35
Dec 06, 2016: TGen outliers study reveals benefits of tumor complexity in glioblastoma 35
Jan 17, 2017: TGen identifies compound that could improve drug development against brain cancer 37
Jan 13, 2016: TGen study published targets SGEF protein in treating glioblastoma brain tumors 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Key Facts 2
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Translational Genomics Research Institute, Deals By Therapy Area, 2011 to YTD 2017 8
The Translational Genomics Research Institute, Medical Devices Deals, 2011 to YTD 2017 9
The Translational Genomics Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
TGen Enters into Research Agreement with Baylor Research Institute 11
BIO5 Oro Valley Enters Into Co-Development Agreement With TGen For Alzheimer’s Disease 12
Virginia G. Piper Cancer Center And TGen Enter Into Co-Development Agreement With Samuel Oschin Comprehensive Cancer Institute 13
Oncoholdings Receives License For ONCO-101 From The Translational Genomics Research Institute 14
The Translational Genomics Research Institute, Key Competitors 15
The Translational Genomics Research Institute, Key Employees 16
The Translational Genomics Research Institute, Other Locations 17
The Translational Genomics Research Institute, Subsidiaries 17
The Translational Genomics Research Institute, Joint Venture 18
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter